Skip to content

ORAMED PHARMACEUTICALS INC.: 10-K filed 2019-11-27

What ORAMED PHARMACEUTICALS INC. reported in its annual report filed 2019-11-27 (fiscal FY 2019): 29 published measures, 73 facts as tagged in accession 0001213900-19-024940.

This filing

Form
10-K (annual report)
Filed
2019-11-27
Fiscal period
fiscal FY 2019
Accession
0001213900-19-024940 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ORAMED PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-08-3134,663,000USD
At 2018-08-3147,397,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-08-3119,393,000USD
At 2018-08-3131,112,000USD
At 2017-08-3119,238,000USD
At 2016-08-3126,190,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-08-313,329,000USD
At 2018-08-314,996,000USD
At 2017-08-313,969,000USD
At 2016-08-313,907,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-09-01 to 2019-08-31-14,355,000USD365
2017-09-01 to 2018-08-31-12,727,000USD365
2016-09-01 to 2017-08-31-10,480,000USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-09-01 to 2019-08-31-12,940,000USD365
2017-09-01 to 2018-08-31-14,657,000USD365
2016-09-01 to 2017-08-31-5,831,000USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-09-01 to 2019-08-3115,000USD365
2017-09-01 to 2018-08-315,000USD365
2016-09-01 to 2017-08-317,000USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2018-09-01 to 2019-08-312,703,000USD365
2017-09-01 to 2018-08-312,449,000USD365
2016-09-01 to 2017-08-312,456,000USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-09-01 to 2018-08-3122,654,000USD365
2016-09-01 to 2017-08-311,586,000USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-09-01 to 2019-08-3111,259,000USD365
2017-09-01 to 2018-08-31-7,004,000USD365
2016-09-01 to 2017-08-314,302,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-08-31-81,103,000USD
At 2018-08-31-69,223,000USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-09-01 to 2019-08-31300,000USD365
2016-09-01 to 2017-08-31400,000USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-08-3124,000USD
At 2018-08-3117,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-09-01 to 2019-08-31808,000USD365
2017-09-01 to 2018-08-311,547,000USD365
2016-09-01 to 2017-08-311,575,000USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-09-01 to 2019-08-31-14,631,000USD365
2017-09-01 to 2018-08-31-13,527,000USD365
2016-09-01 to 2017-08-31-10,771,000USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-08-3133,324,000USD
At 2018-08-3131,037,000USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-08-315,308,000USD
At 2018-08-314,553,000USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2018-09-01 to 2019-08-3190,000USD365
2017-09-01 to 2018-08-31-86,000USD365
2016-09-01 to 2017-08-31187,000USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-09-01 to 2019-08-3113,522,000USD365
2017-09-01 to 2018-08-3111,979,000USD365
2016-09-01 to 2017-08-3110,281,000USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-08-3117,383,359shares
At 2018-08-3117,369,875shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-08-31702,000USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2019-08-31116,000USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2019-08-319,658,000USD
At 2018-08-3111,388,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-08-31271,000USD
At 2018-08-31313,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-08-311,042,000USD
At 2018-08-31574,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-09-01 to 2019-08-31-14,055,000USD365
2017-09-01 to 2018-08-31-12,727,000USD365
2016-09-01 to 2017-08-31-10,080,000USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-09-01 to 2019-08-31-14,355,000USD365
2017-09-01 to 2018-08-31-12,426,000USD365
2016-09-01 to 2017-08-31-10,185,000USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-09-01 to 2019-08-313,722,000USD365
2017-09-01 to 2018-08-314,083,000USD365
2016-09-01 to 2017-08-312,759,000USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-09-01 to 2019-08-318,000USD365
2017-09-01 to 2018-08-316,000USD365
2016-09-01 to 2017-08-315,000USD365

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2018-09-01 to 2019-08-31300,000USD365
2016-09-01 to 2017-08-31400,000USD365

Inspect the source

Entity
ORAMED PHARMACEUTICALS INC. / CIK 0001176309
Captured
2026-09-20T07:44:51.277Z
SEC response SHA-256
4de2fa61f6e99a9334450df93c3a54e105e138fae12a8b631b4bdc95f4c98422

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001176309.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))